Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06286397 · ClinicalTrials.gov registry record · Phase 2

Topical Anti-Androgens in Pilonidal Sinus Disease

A Phase 2 study of Pilonidal Disease and Pilonidal Sinus, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT06286397 is a Phase 2 study of Pilonidal Disease and Pilonidal Sinus that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 75 participants, below the 134-participant average among 5 other Pilonidal Disease trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06286397, a Phase 2 study of Pilonidal Disease and Pilonidal Sinus, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are: * Does clascoterone improve the severity of pilonidal disease as scored by a physician? * Does clascoterone improve patient symptoms due to pilonidal disease? * Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Participants will apply clascoterone or a placebo cream to the diseased area for 3 months. They will be assessed every 4 weeks for disease severity assessed by a physician viewing patient photos and a symptom-based survey. Researchers will compare participants who received clascoterone treatment to those who received placebo.

Interventions

  • DRUG Vehicle Cream
  • DRUG 1% Clascoterone

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-01-10
Est. Completion 2028-01-01
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT06286397

The ClinicalTrials.gov registry entry for NCT06286397 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 5 other Pilonidal Disease trials with a reported enrollment target (44% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Pilonidal Disease appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Cream is the first listed.

NCT06286397 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06286397 about?

NCT06286397 is a clinical study titled "Topical Anti-Androgens in Pilonidal Sinus Disease". The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are: * Does clascoterone improve the severity of pilonidal disease as scored by...

What is the current status of trial NCT06286397?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-01-10. Estimated completion is 2028-01-01.

What conditions does trial NCT06286397 study?

This clinical trial studies the following conditions: Pilonidal Disease, Pilonidal Sinus, Pilonidal Disease of Natal Cleft, Pilonidal Cyst.

What interventions are being tested in trial NCT06286397?

The interventions under investigation include: Vehicle Cream (DRUG), 1% Clascoterone (DRUG).

Who is sponsoring clinical trial NCT06286397?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06286397 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pilonidal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.